Source: The ASCO Post, May 2025
Researchers may have uncovered early indications of the clinical benefit of niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair, according to a recent study published by Kim et al in JCO Precision Oncology.
Background
The U.S. Food and Drug Administration approved tumor-infiltrating lymphocyte therapy for patients with advanced melanoma who have previously received anti–PD-1 antibody therapy and a combination of BRAF/MEK inhibitors among those with BRAF V600–mutated tumors.
“Despite these available, approved combination therapies, many patients’ disease progresses or recurs, reinforcing the critical need for new, targeted treatments,” stressed lead study author Kevin Kim, MD, a medical oncologist at the Sutter California Pacific Medical Center. “Our goal is to advance this research to help guide and inform the care of patients who have limited therapeutic options,” he added.